Rockwell Medical (RMTI) is having a good Wednesday morning. The stock is up 6.4% in premarket trading after the company announced it had renewed a product purchase agreement with aQua Dialysis. The deal runs for two years, with options for two additional one-year extensions, and covers the supply of liquid and dry hemodialysis concentrates.
This isn't a new relationship — Rockwell has been working with aQua for a while. The renewal just reinforces that partnership. “We are pleased to continue supporting aQua Dialysis through our renewed agreement that reflects the strength of our long-standing relationship,” said Tim Chole, Rockwell's Chief Commercial Officer.
For a company like Rockwell, which focuses on essential products for dialysis providers, keeping a customer like aQua on board is a solid vote of confidence. It suggests the products are reliable and the service is good. But the market's reaction — a 6.4% pop — also shows that investors were paying attention.
What the Charts Say
From a technical perspective, RMTI is sitting right on its 20-day moving averages. Both the 20-day simple moving average (SMA) and the 20-day exponential moving average (EMA) are at 84 cents, which makes this level a near-term “line in the sand.” If the bounce holds, it could signal some short-term strength. If it doesn't, well, that's a different story.
The bigger picture is less rosy. The stock is trading 7.1% below its 50-day SMA, 11.4% below its 100-day SMA, and 19.9% below its 200-day SMA. That's a lot of red. Momentum is also cautious: the MACD (moving average convergence divergence) is below its signal line, and the histogram is negative. In plain English, that means the recent upward push is losing steam compared to the prior upswing. Rallies might struggle unless buyers can push the MACD back above that baseline.
The longer-term structure remains bearish, highlighted by a death cross that formed back in November 2025, when the 50-day SMA fell below the 200-day SMA. That's a classic sign of a downtrend. The stock put in a swing high in March and a swing low in May, and it's still trying to stabilize after printing its 52-week low in May.
Here are the key levels to watch:
- Key Resistance: $1.05 — this aligns with the 200-day SMA/EMA, a common level where longer-term downtrends cap rebounds.
- Key Support: 74 cents — the 52-week low zone from May, a key reference if the bounce fails.
So, the renewed deal is good news, but the stock still has a lot of technical ground to cover. For now, traders are watching whether that 20-day moving average can hold as support. If it does, the bounce might have legs. If not, the 74-cent level becomes the next big question mark.
Photo via Shutterstock
